166 related articles for article (PubMed ID: 27756883)
1. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials.
Zhang H; Huang Z; Zou X; Liu T
Oncotarget; 2016 Dec; 7(50):82473-82481. PubMed ID: 27756883
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ahmadizar F; Onland-Moret NC; de Boer A; Liu G; Maitland-van der Zee AH
PLoS One; 2015; 10(9):e0136324. PubMed ID: 26331473
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
Chen J; Lu Y; Zheng Y
Drug Des Devel Ther; 2015; 9():4751-60. PubMed ID: 26316712
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
5. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
7. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon.
Sharma K; Marcus JR
Ann Plast Surg; 2013 Oct; 71(4):434-40. PubMed ID: 22868316
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
Totzeck M; Mincu RI; Rassaf T
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862931
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
Hapani S; Sher A; Chu D; Wu S
Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis.
Wang ZP; Zhang HF; Zhang F; Hu BL; Wei HT; Guo YY
Eur J Clin Pharmacol; 2015 May; 71(5):517-24. PubMed ID: 25845654
[TBL] [Abstract][Full Text] [Related]
13. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
14. Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data.
Liu M; Zheng Y; Chen Z; Qiu Y; Pan Z; Cai Z; Shi Y; Cheng J; Yao W
Tumour Biol; 2017 Jul; 39(7):1010428317714897. PubMed ID: 28714372
[TBL] [Abstract][Full Text] [Related]
15. Impaired wound healing secondary to bevacizumab.
Ahn JW; Shalabi D; Correa-Selm LM; Dasgeb B; Nikbakht N; Cha J
Int Wound J; 2019 Aug; 16(4):1009-1012. PubMed ID: 31111622
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
17. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis.
Qu CY; Zheng Y; Zhou M; Zhang Y; Shen F; Cao J; Xu LM
World J Gastroenterol; 2015 Apr; 21(16):5072-80. PubMed ID: 25945023
[TBL] [Abstract][Full Text] [Related]
18. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.
Roviello G; Bachelot T; Hudis CA; Curigliano G; Reynolds AR; Petrioli R; Generali D
Eur J Cancer; 2017 Apr; 75():245-258. PubMed ID: 28242502
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.
Li X; Zhu S; Hong C; Cai H
Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
